Meta-analysis · people

Abaloparatide, teriparatide beat other drugs on spine BMD in men

Checked against the paper Meta-analysisPublished by PepVault

The takeaway

In men with osteoporosis, abaloparatide was among the top options for spine and femoral neck bone density, but it did not lead on total hip density or on side effects.

Kind
Meta-analysis
Studied in
People
Published
2025
Journal
Front Endocrinol (Lausanne)

What they tested

The team wanted to compare how well and how safely five drug options treat osteoporosis in men: abaloparatide, denosumab, teriparatide, oral bisphosphonates and intravenous (IV) bisphosphonates.

How the study was done

A systematic review and Bayesian network meta-analysis, a method that pools published studies to compare several treatments at once, focused on men with osteoporosis. It compared the five drug options on bone mineral density (BMD, a measure of how dense bones are) and on adverse events (side effects).

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking abaloparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Abaloparatide and teriparatide did significantly better than the other drugs for raising BMD at the lumbar spine (lower back) and the femoral neck (the top of the thigh bone near the hip joint). Oral bisphosphonates did best for total hip BMD, where teriparatide did less well. On safety, teriparatide did best for all adverse events, and oral bisphosphonates did best for lowering severe adverse events.

What it doesn’t show

This study covers men only. It compares the drugs by pooling separate studies rather than testing them side by side in a single trial.

The paper

Chen et al. Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of male osteoporosis: a systematic review and Bayesian network meta-analysis. Front Endocrinol (Lausanne). 2025.

The compounds

More studies on Abaloparatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking abaloparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo